Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

The Biology and Lab Tests Behind Your Diagnosis

At a Glance

Dysbetalipoproteinemia (DBL) is driven by the APOE e2/e2 genetic variant, preventing the liver from clearing remnant cholesterol. Because standard tests miscalculate LDL in DBL, doctors must use specialized tests like the non-HDL-C to ApoB ratio or beta-quantification for an accurate diagnosis.

To understand Dysbetalipoproteinemia (DBL), you have to look beneath the surface of a standard cholesterol test. While most people focus on LDL, DBL is a disease of remnant lipoproteins—the “half-digested” particles of fat and cholesterol that your body is failing to recycle [1][2].

The Genetics of the “Weak Grip”

The foundation of DBL is almost always a specific genetic profile called APOE e2/e2 [3].

  • The APOE Protein: Your body uses a protein called Apolipoprotein E (ApoE) as a “hook” or “handle” that allows the liver to grab fat particles out of the blood [3][2].
  • The e2 Variant: Most people have the e3 or e4 version of this protein, which has a strong grip. The e2 variant has a structural change that makes its “grip” on the liver’s receptors extremely weak [4].
  • The Recessive Nature: Because this is a recessive trait, you generally need to inherit the e2 variant from both parents (e2/e2) to have the condition [5]. If you have even one copy of e3 or e4, that “strong” protein is usually enough to keep your blood clear [5].

“Beta-VLDL”: The Dangerous Actor

When your liver can’t “grab” these particles, they stay in your blood and transform into beta-VLDL [6][7]. These are the “bad actors” in DBL.

  • Highly Atherogenic: Unlike normal LDL, these remnant particles are “pre-loaded” with cholesterol and are the perfect size to get trapped in your artery walls [8][9].
  • Foam Cells: Once in the artery wall, they are swallowed by immune cells, turning them into foam cells, which are the building blocks of dangerous plaque [10][11].

Why Standard Labs Miss the Diagnosis

If you look at a standard lipid panel, DBL often looks like “Mixed Hyperlipidemia”—meaning both your triglycerides and your cholesterol are high [12][13].

  1. The Calculation Error: Most labs “calculate” your LDL (using something called the Friedewald equation). In DBL, this calculation is often wildly inaccurate because the math wasn’t designed for remnant particles [14][15].
  2. The “Equal” Look: A major clue for DBL is when your Total Cholesterol and your Triglycerides are both elevated to a similar degree (for example, both are around 300 mg/dL) [16][12].

Definitive Diagnostic Tools

To confirm DBL, doctors use more specialized tools that look specifically for those “half-digested” remnants.

1. Beta-Quantification (The Gold Standard)

This test uses an ultracentrifuge—a machine that spins your blood at incredibly high speeds to separate fats by their density [12][16].

  • It allows doctors to see the beta-VLDL directly [12].
  • If the ratio of cholesterol in your VLDL particles compared to your total triglycerides is high (typically >0.30 in mg/dL), the diagnosis is confirmed [17][18].

2. The non-HDL-C to ApoB Ratio

Since ultracentrifugation is expensive and not always available, doctors often use a clever “shortcut” called the non-HDL-C to ApoB ratio [19][20].

  • Non-HDL-C: This measures all the bad cholesterol in your blood.
  • ApoB: This measures the number of bad particles you have.
  • The Logic: In DBL, each particle (ApoB) is stuffed with an unusually large amount of cholesterol (remnants). Therefore, if your Non-HDL-C is very high compared to your ApoB (a ratio >1.45 mg/mg or >3.69 mmol/g), it is a loud signal that you have DBL [19][20].
  • Tip: Don’t worry about doing this math yourself—just ask your doctor to calculate the Non-HDL-C to ApoB ratio for you.

By checking these specific numbers, you and your doctor can move past the “guesswork” of standard testing and focus on the real problem: the remnants [14][13].

Common questions in this guide

Why do standard cholesterol tests miss Dysbetalipoproteinemia?
Standard lipid panels use a calculation for LDL that was not designed for remnant particles, causing wildly inaccurate results for DBL patients. A major diagnostic clue is when your Total Cholesterol and Triglycerides are both elevated to a roughly equal, high number.
What does the APOE e2/e2 genotype mean for my cholesterol?
The APOE gene creates a protein that helps your liver clear fat particles from your blood. Having the recessive e2/e2 variant means this protein has a very weak grip, causing dangerous remnant lipoproteins (beta-VLDL) to build up in your arteries.
What is the non-HDL-C to ApoB ratio?
This is a diagnostic calculation used to detect DBL without expensive ultracentrifuge testing. A ratio higher than 1.45 mg/mg indicates that your cholesterol particles are unusually stuffed with fats, which is a loud signal for DBL.
What is beta-quantification and why is it used?
Beta-quantification is the gold standard test for diagnosing DBL. It uses a machine called an ultracentrifuge to spin your blood at high speeds, separating fats by density so doctors can directly measure the dangerous beta-VLDL remnant particles.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Since standard LDL-C calculations are often inaccurate for people with my condition, what is the best way for us to track my 'true' cholesterol levels?
  2. 2.Can we calculate my non-HDL-C to ApoB ratio from my current labs, and does it fall above the threshold (e.g., 1.45 mg/mg) for DBL?
  3. 3.If my diagnosis is still uncertain, is it possible to order a beta-quantification test via ultracentrifugation?
  4. 4.Does my ApoE e2/e2 genotype mean I am a 'recessive' carrier, and how does that affect the risk for my children?
  5. 5.Are there other ApoB-containing particles, besides LDL, that we should be monitoring?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Dysbetalipoproteinemia: an extreme disorder of remnant metabolism.

    Marais D

    Current opinion in lipidology 2015; (26(4)):292-7 doi:10.1097/MOL.0000000000000192.

    PMID: 26103610
  2. 2

    Dysbetalipoproteinemia and other lipid abnormalities related to apo E.

    Cenarro A, Bea AM, Gracia-Rubio I, Civeira F

    Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2021; (33 Suppl 2()):50-55 doi:10.1016/j.arteri.2021.01.002.

    PMID: 34006354
  3. 3

    Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder.

    Koopal C, Marais AD, Visseren FL

    Current opinion in endocrinology, diabetes, and obesity 2017; (24(2)):133-139 doi:10.1097/MED.0000000000000316.

    PMID: 28098593
  4. 4

    Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes.

    Guo JL, Braun D, Fitzgerald GA, et al.

    Cell 2025; (188(1)):187-206.e26 doi:10.1016/j.cell.2024.10.027.

    PMID: 39532095
  5. 5

    Adiposity and the development of dyslipidemia in APOE ε2 homozygous subjects: A longitudinal analysis in two population-based cohorts.

    Heidemann BE, Wolters FJ, Kavousi M, et al.

    Atherosclerosis 2021; (325()):57-62 doi:10.1016/j.atherosclerosis.2021.04.001.

    PMID: 33892328
  6. 6

    Type III Hyperlipoproteinemia: Still Worth Considering?

    Blum CB

    Progress in cardiovascular diseases 2016; (59(2)):119-124 doi:10.1016/j.pcad.2016.07.007.

    PMID: 27481046
  7. 7

    Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

    Heidemann BE, Koopal C, Baass A, et al.

    Clinical genetics 2022; (102(4)):253-261 doi:10.1111/cge.14185.

    PMID: 35781703
  8. 8

    Postprandial Hyperlipidemia and Remnant Lipoproteins.

    Masuda D, Yamashita S

    Journal of atherosclerosis and thrombosis 2017; (24(2)):95-109 doi:10.5551/jat.RV16003.

    PMID: 27829582
  9. 9

    Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.

    Sniderman AD, Thanassoulis G, Glavinovic T, et al.

    JAMA cardiology 2019; (4(12)):1287-1295 doi:10.1001/jamacardio.2019.3780.

    PMID: 31642874
  10. 10

    Hyperlipidemic myeloma, a rare form of acquired dysbetalipoproteinemia, in an HIV seropositive African female.

    Seedat F, Patel M, Phillip V, et al.

    Clinica chimica acta; international journal of clinical chemistry 2021; (520()):71-75 doi:10.1016/j.cca.2021.05.027.

    PMID: 34052205
  11. 11

    Role of VLDL receptor in atherogenesis.

    Takahashi S

    Current opinion in lipidology 2021; (32(4)):219-225 doi:10.1097/MOL.0000000000000760.

    PMID: 34227576
  12. 12

    The clinical and laboratory investigation of dysbetalipoproteinemia.

    Boot CS, Luvai A, Neely RDG

    Critical reviews in clinical laboratory sciences 2020; (57(7)):458-469 doi:10.1080/10408363.2020.1745142.

    PMID: 32255405
  13. 13

    Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype.

    Bea AM, Cenarro A, Marco-Bened V, et al.

    Clinical chemistry 2023; (69(2)):140-148 doi:10.1093/clinchem/hvac213.

    PMID: 36644927
  14. 14

    Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol measurement in Familial Dysbetalipoproteinemia.

    Heidemann BE, Koopal C, Roeters van Lennep JE, et al.

    Clinica chimica acta; international journal of clinical chemistry 2023; (539()):114-121 doi:10.1016/j.cca.2022.11.035.

    PMID: 36493875
  15. 15

    Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?

    Higgins V, Leiter LA, Delaney SR, Beriault DR

    Clinical biochemistry 2022; (99()):60-68 doi:10.1016/j.clinbiochem.2021.10.003.

    PMID: 34656564
  16. 16

    The spectrum of type III hyperlipoproteinemia.

    Sniderman AD, de Graaf J, Thanassoulis G, et al.

    Journal of clinical lipidology 2018; (12(6)):1383-1389 doi:10.1016/j.jacl.2018.09.006.

    PMID: 30318453
  17. 17

    Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol.

    Sampson M, Wolska A, Meeusen JW, et al.

    Frontiers in genetics 2022; (13()):935257 doi:10.3389/fgene.2022.935257.

    PMID: 35910208
  18. 18

    Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm.

    Varghese B, Park J, Chew E, et al.

    Journal of clinical lipidology 2021; (15(1)):104-115.e9 doi:10.1016/j.jacl.2020.09.011.

    PMID: 33189625
  19. 19

    A simplified diagnosis algorithm for dysbetalipoproteinemia.

    Paquette M, Bernard S, Blank D, et al.

    Journal of clinical lipidology 2020; (14(4)):431-437 doi:10.1016/j.jacl.2020.06.004.

    PMID: 32631794
  20. 20

    Evaluation of the Non-HDL Cholesterol to Apolipoprotein B Ratio as a Screening Test for Dysbetalipoproteinemia.

    Boot CS, Middling E, Allen J, Neely RDG

    Clinical chemistry 2019; (65(2)):313-320 doi:10.1373/clinchem.2018.292425.

    PMID: 30538126

This page explains the biology and laboratory testing of Dysbetalipoproteinemia for educational purposes only. Always consult your doctor or lipid specialist to interpret your specific lipid panels and genetic test results.

Get notified when new evidence is published on Dysbetalipoproteinemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.